Biogen (BIIB) Granted EU Approval of SKYCLARYS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to Biogen (BIIB) Granted EU Approval of SKYCLARYS

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

February 12, 2024 4:06 PM EST

Friedreichs ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorderTreatment with SKYCLARYS improved patient function compared to placeboBiogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients

CAMBRIDGE, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has authorized SKYCLARYS® (omaveloxolone) for the treatment of Friedreichs... More